| __timestamp | Vertex Pharmaceuticals Incorporated | argenx SE |
|---|---|---|
| Wednesday, January 1, 2014 | 305409000 | 4241601.57 |
| Thursday, January 1, 2015 | 377080000 | 5392385.38 |
| Friday, January 1, 2016 | 432829000 | 7370036.73 |
| Sunday, January 1, 2017 | 496079000 | 14970357 |
| Monday, January 1, 2018 | 557616000 | 31413266 |
| Tuesday, January 1, 2019 | 658498000 | 72279461 |
| Wednesday, January 1, 2020 | 770456000 | 183907682 |
| Friday, January 1, 2021 | 840100000 | 307644000 |
| Saturday, January 1, 2022 | 944700000 | 472132000 |
| Sunday, January 1, 2023 | 1136600000 | 709539000 |
| Monday, January 1, 2024 | 1464300000 |
In pursuit of knowledge
In the competitive landscape of the pharmaceutical industry, understanding spending patterns is crucial. Over the past decade, Vertex Pharmaceuticals and argenx SE have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Vertex Pharmaceuticals has consistently increased its SG&A spending, growing by approximately 272%, from $305 million to over $1.1 billion. This reflects a strategic investment in expanding its market presence and operational capabilities.
Conversely, argenx SE, a rising star in the biotech sector, has demonstrated a staggering growth in SG&A expenses, skyrocketing from a modest $4 million in 2014 to $709 million in 2023. This represents an exponential increase of over 16,600%, underscoring its aggressive expansion and scaling efforts. These trends highlight the dynamic nature of the industry, where strategic spending is pivotal for growth and competitiveness.
Eli Lilly and Company and Vertex Pharmaceuticals Incorporated: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Takeda Pharmaceutical Company Limited Trends and Insights
Vertex Pharmaceuticals Incorporated or Ascendis Pharma A/S: Who Manages SG&A Costs Better?
Vertex Pharmaceuticals Incorporated and Cytokinetics, Incorporated: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Rhythm Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Vertex Pharmaceuticals Incorporated and Veracyte, Inc.
Vertex Pharmaceuticals Incorporated vs Wave Life Sciences Ltd.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Zoetis Inc. and argenx SE
argenx SE or Alpine Immune Sciences, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of argenx SE and CRISPR Therapeutics AG
Who Optimizes SG&A Costs Better? argenx SE or Bausch Health Companies Inc.
Cost Management Insights: SG&A Expenses for argenx SE and ACADIA Pharmaceuticals Inc.